The company manufactures synthetic bristles and monofilaments made from nylon and polypropylene, primarily serving the industrial brush and medical suture markets.
The company operates in a commoditized segment of the plastics industry with no evidence of pricing power, as net margins are razor-thin at 2% and revenue growth is stagnant. While they claim a reputation for quality, the financials show a lack of competitive advantage, with high sensitivity to raw material price fluctuations and power shortages.
Capital allocation is poor, characterized by persistent net losses or negligible profits and a total lack of dividends. The company relies on inter-corporate loans from related parties to sustain operations, and significant funds are tied up in non-productive security deposits and disputed land titles.
The investment collapsed as the disputed land title—the company's primary asset—was ruled against them by the Bombay High Court, evaporating the balance sheet's core value. Simultaneously, the lack of internal audit controls and reliance on related-party loans led to a liquidity crunch when those unsecured credit lines were withdrawn. With stagnant revenue and razor-thin margins, the business could not absorb rising raw material costs, leading to a total cessation of operations and a delisting following the promoter's persistent regulatory non-compliance.
RichFakir rates Garware Synthetics Ltd's business quality as poor — 21/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Garware Synthetics Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Garware Synthetics Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Garware Synthetics Ltd's fair value is about ₹4 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →